MRK · 8-K · 20260804PR090045

Geographic Market Commentary

Merck & Co., Inc. · 2026-08-04 · Importance 17 · Surprise 24

Demand was stronger for GARDASIL/GARDASIL 9 in Asia Pacific and Europe, with favorable timing of European tenders, although certain other international markets were weaker. WINREVAIR showed early international launch uptake particularly in Japan and Europe, in addition to continued U.S. growth. WELIREG also benefited from continued launch uptake in Japan and several other international markets. LAGEVRIO demand declined sharply in Japan and the United States, while JANUVIA/JANUMET demand weakened in China and most other international markets.